Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares a comparative analysis of the safety and efficacy of lisocabtagene maraleucel (liso-cel), an anti-CD19 CAR T-cell therapy, and mosunetuzumab, a CD20xCD3 bispecific antibody, in the treatment of third line (3L) or later relapsed/refractory (R/R) follicular lymphoma (FL). Utilizing data from two clinical trials (TRANSCEND FL; NCT04245839, GO29781; NCT02500407), a matching-adjusted indirect comparison (MAIC) highlights that liso-cel demonstrates superior efficacy and a lower incidence of high-grade adverse events (AEs). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.